Insulet (NASDAQ:PODD) Given New $375.00 Price Target at The Goldman Sachs Group

Insulet (NASDAQ:PODD) had its price target lowered by The Goldman Sachs Group from $399.00 to $375.00 in a report released on Wednesday,MarketScreener reports. The firm currently has a buy rating on the medical instruments supplier’s stock.

Other equities research analysts have also recently issued reports about the stock. Oppenheimer raised their price objective on shares of Insulet from $324.00 to $365.00 and gave the stock an “outperform” rating in a research report on Monday, September 8th. Truist Financial started coverage on shares of Insulet in a research report on Monday, June 16th. They set a “buy” rating and a $365.00 price objective for the company. Jefferies Financial Group restated a “buy” rating on shares of Insulet in a research report on Thursday, August 7th. Wall Street Zen upgraded shares of Insulet from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Finally, Barclays lifted their price target on shares of Insulet from $266.00 to $300.00 and gave the company an “equal weight” rating in a research report on Thursday, August 21st. Sixteen investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $345.47.

Insulet Price Performance

Insulet stock opened at $305.98 on Wednesday. Insulet has a 12-month low of $225.37 and a 12-month high of $353.50. The stock has a market cap of $21.54 billion, a P/E ratio of 93.00, a PEG ratio of 2.56 and a beta of 1.40. The company has a 50-day moving average price of $320.45 and a 200 day moving average price of $297.85. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The firm had revenue of $649.10 million during the quarter, compared to analysts’ expectations of $612.31 million. During the same period last year, the business earned $0.55 earnings per share. Insulet’s revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Sell-side analysts anticipate that Insulet will post 3.92 earnings per share for the current year.

Insider Activity at Insulet

In other Insulet news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the transaction, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.39% of the company’s stock.

Institutional Trading of Insulet

Several institutional investors have recently modified their holdings of the stock. Praxis Investment Management Inc. lifted its position in shares of Insulet by 55.9% during the 3rd quarter. Praxis Investment Management Inc. now owns 2,588 shares of the medical instruments supplier’s stock worth $799,000 after buying an additional 928 shares during the last quarter. Corient Private Wealth LLC lifted its position in shares of Insulet by 7.3% during the 2nd quarter. Corient Private Wealth LLC now owns 10,307 shares of the medical instruments supplier’s stock worth $3,238,000 after buying an additional 700 shares during the last quarter. Texas Permanent School Fund Corp lifted its position in shares of Insulet by 46.9% during the 2nd quarter. Texas Permanent School Fund Corp now owns 11,387 shares of the medical instruments supplier’s stock worth $3,578,000 after buying an additional 3,633 shares during the last quarter. Reynders McVeigh Capital Management LLC lifted its position in shares of Insulet by 4.6% during the 2nd quarter. Reynders McVeigh Capital Management LLC now owns 2,013 shares of the medical instruments supplier’s stock worth $632,000 after buying an additional 88 shares during the last quarter. Finally, Osaic Holdings Inc. lifted its position in shares of Insulet by 152.9% during the 2nd quarter. Osaic Holdings Inc. now owns 8,781 shares of the medical instruments supplier’s stock worth $2,709,000 after buying an additional 5,309 shares during the last quarter.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.